BioAge Labs(NASDAQ) BIOA

BioAge makes drugs to treat metabolic diseases by studying how people age. These medicines help people with heart issues, eye swelling, and weight management. The company finds new treatments by looking at data from human biobanks.

Medicines for a Longer Life

• BGE-102: Oral drug that blocks a protein called NLRP3 to reduce inflammation in the heart and eyes.
• Obesity Treatments: Experimental drugs designed to mimic exercise signals in the body to help people lose weight.
• Discovery Platform: Analysis system that uses 50 years of human data to find new ways to treat aging.

Partnerships and Progress

• Signed an option agreement in June 2025 with JiKang Therapeutics for a new obesity treatment.
• Maintains research collaborations with Eli Lilly and Company and Novartis Pharma AG for drug discovery.
• Reported positive interim data for its lead heart drug program in January 2026.
• Filed a provisional patent for new oral obesity drug candidates in May 2025.

Decades of Human Data

BioAge analyzes biological samples collected from the same people over several decades to track aging. This allows the company to find treatments that match the biology of people who stay healthy longer.

Tracking the 2025 Numbers

• Revenue reached $3.1 million in Q4 2025, up from zero in 2024.
• Operating loss deepened to $28.4 million in Q4 2025, a 12.1% decline year-over-year.
• Net loss worsened to $25.9 million in Q4 2025, a 22.8% drop from the prior year.
• Free cash flow hit negative $28.4 million in Q4 2025, down 449.2% from 2024.

Bottom Line

BioAge has grown from a research platform into a clinical developer targeting the biology of aging. Its focus on chronic diseases and major pharmaceutical partnerships positions it as a specialized biotechnology player.